Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.54 |
| ▸ | CNR2 | P34972 | 11/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15606979 | 1.00 | CNR1 (0.54) | CNR1CNR2TRPV1ALDH1A1FAAH | |
| SCHEMBL9209602 | 0.82 | CNR2 (0.70) | CNR1CNR2TRPV1ALDH1A1FAAH | |
| SCHEMBL15606927 | 0.80 | CNR2 (0.71) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL15526152 | 0.80 | CNR2 (0.71) | CNR1CNR2ALDH1A1FAAHMAPT | |
| SCHEMBL16001846 | 0.78 | CNR2 (0.58) | CNR1CNR2TRPV1ALDH1A1FAAH | |
| SCHEMBL8537374 | 0.77 | CNR2 (0.54) | CNR1CNR2TRPV1ALDH1A1FAAH | |
| SCHEMBL4341647 | 0.77 | TRPV1 (0.50) | CNR1CNR2TRPV1 | |
| SCHEMBL22858735 | 0.77 | TRPV1 (0.50) | CNR1CNR2TRPV1 | |
| SCHEMBL30526487 | 0.77 | TRPV1 (0.50) | CNR1CNR2TRPV1 | |
| SCHEMBL9204695 | 0.77 | TRPV1 (0.75) | CNR1CNR2TRPV1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847178-B1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | US HEALTH (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9422308-B2 | Derivatives of docosahexaenoylethanolamide and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031878-A1 | DERIVATIVES OF DOCOSAHEXAENOYLETHANOLAMIDE AND USES THEREOF | GAP43, DGAT2, DCX | CNR1 502/4885CNR2 328/4885TRPV1 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.